- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07637877
Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study
This study focuses on people with HIV who experience incomplete immune reconstitution despite suppressive antiretroviral therapy (ART), characterized by persistently low CD4⁺ T cell counts and residual inflammation. The underlying cause is largely attributed to the persistent HIV latent reservoir. Recent evidence indicates that rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) commonly used in ART, has an immunomodulatory function beyond its antiviral activity. It activates the CARD8 inflammasome - an intracellular "kill switch" - triggering pyroptosis selectively in HIV-infected cells. In this study, rilpivirine will be added to suppressive ART in patients with incomplete immune reconstitution. The investigators hypothesize that this strategy will reduce the latent reservoir, restore CD4⁺ T cell counts and function, attenuate excessive immune activation, and ultimately improve long-term clinical outcomes.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ruonan Xu, MD
- Numéro de téléphone: +8618611314169
- E-mail: xuruonan2004@aliyun.com
Lieux d'étude
-
-
-
Beijing, Chine, 100039
- Recrutement
- 302 Hospital
-
Contact:
- Fu-Sheng Wang, MD
- Numéro de téléphone: 01066933328
- E-mail: fswang302@163.com
-
Guangzhou, Chine
- Recrutement
- Guangzhou Eighth People's Hospital
-
Contact:
- Xiaoping Tang
- Numéro de téléphone: 020-83838688
- E-mail: tangxp@gzhmu.edu.cn
-
Guangzhou, Chine
- Recrutement
- The Third Affiliated Hospital of Sun Yat-sen University
-
Contact:
- Ying Zhang
- Numéro de téléphone: 020-85253333
- E-mail: zhangyg5@mail.sysu.edu.cn
-
Shenzhen, Chine
- Recrutement
- Shenzhen Third People's Hospital
-
Contact:
- Haitao Zhang
- Numéro de téléphone: 0755-61222333
- E-mail: 497465011@qq.com
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 100039
- Recrutement
- The Fifth Medical Center of PLA General Hospital
-
Contact:
- Fu-Sheng Wang, MD
- Numéro de téléphone: 01066933328
- E-mail: fswang302@163.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients with incomplete immune reconstitution, aged between 18 and 65 years (inclusive).
- At enrollment, have received antiretroviral therapy (ART) for more than 4 years, with plasma HIV-RNA below the lower limit of detection (VL < 50 copies/mL) for more than 3 years, while CD4⁺ T cell count remains persistently below 350 cells/μL.
- Within 1 year prior to enrollment, CD4⁺ T cell count remains persistently below 350 cells/μL but above 200 cells/μL.
- Currently receiving a dolutegravir (DTG)-based ART regimen (e.g., DTG plus lamivudine, or the fixed-dose combination DTG/3TC/ABC) for ≥ 1 year, with no relevant drug resistance detected by high-precision resistance testing; no change in the core ART regimen within 1 year prior to enrollment (adjustments of auxiliary medications for side effect management are permitted); and agree to continue the current integrase inhibitor-based regimen for at least 1 year after enrollment.
- Willing and able to provide written informed consent prior to any study-related procedures, and to comply with all study requirements.
Exclusion Criteria:
- Co-infection with other viruses: positive for any of HBV, HCV, HDV, or HEV; or CMV/EBV viral load > 1000 copies/mL.
- HIV-2 infection alone or co-infection with HIV-1 and HIV-2.
- History of using efavirenz or rilpivirine within 2 years prior to enrollment.
- History of NNRTI resistance.
- Clinical signs suggestive of other serious diseases.
- Long-term use of corticosteroids or other immunosuppressive agents.
- Co-existing severe AIDS-related or non-AIDS-related events.
- Co-existing severe underlying diseases of other systems not related to AIDS.
- Other severe organic diseases or psychiatric disorders, including any uncontrolled clinically significant disease of the urinary, circulatory, respiratory, nervous, psychiatric, digestive, endocrine, immune systems, or malignancy.
- Receipt of immunosuppressive or systemic cytotoxic therapy within 6 months prior to screening.
- Evidence of substance abuse within 6 months prior to enrollment, or a positive urine drug screen.
- Current participation in another clinical trial that may conflict with the treatment protocol or outcome measures of this study.
- Pregnancy, breastfeeding, or women who have a desire to become pregnant.
- Inability or unwillingness to provide informed consent or comply with study requirements.
- Any other serious condition that may interfere with the conduct of the clinical trial.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: cART
Participants receive standard combination antiretroviral therapy (cART) alone (without rilpivirine). |
Participants receive standard combination antiretroviral therapy (cART) alone |
|
Expérimental: cART plus Rilpivirine
Participants receive standard combination antiretroviral therapy (cART) plus rilpivirine |
Participants receive standard combination antiretroviral therapy (cART) plus rilpivirine |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
CD4⁺ T cell count
Délai: Baseline to week 36
|
Baseline to week 36
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants with treatment-emergent adverse events
Délai: From baseline to 36 weekks
|
Safety will be assessed by monitoring and recording all adverse events (AEs), serious adverse events (SAEs), and AEs leading to treatment discontinuation. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
From baseline to 36 weekks
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- KY-2025-11-209-2
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .